Evidence map›Paper›PMID 37989732›Full record

ArticleCell death & disease2023

3,4-dimethoxychalcone induces autophagy and reduces neointimal hyperplasia and aortic lesions in mouse models of atherosclerosis.

Giulia Cerrato, Carlota Alvarez-Lucena, Allan Sauvat, Yanhua Hu, Sabrina Forveille, Guo Chen, Sylvère Durand, Fanny Aprahamian, Marion Leduc, Omar Motiño and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. The geroprotective potential of chalcones.Nature communications · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Giulia CerratoMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Carlota Alvarez-LucenaInstituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM) and Centro de Investigación en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.ORCID 0000-0002-7115-2111
Allan SauvatMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.ORCID 0000-0001-7076-8638
Yanhua HuThe Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.
Sabrina ForveilleMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Guo ChenMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.ORCID 0000-0001-5354-3816
Sylvère DurandMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Fanny AprahamianMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Marion LeducMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Omar MotiñoMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.ORCID 0000-0002-3858-0966
Lisardo BoscáInstituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM) and Centro de Investigación en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.ORCID 0000-0002-0253-5469
Qingbo XuThe Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0002-6414-2273
Oliver KeppMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France. captain.olsen@gmail.com.ORCID 0000-0002-6081-9558
Guido KroemerMetabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France. kroemer@orange.fr.ORCID 0000-0002-9334-4405
Inserm · FRCentral South University · CNInstituto de Investigaciones Biomédicas Sols-Morreale · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autophagy inducers can prevent cardiovascular aging and age-associated diseases including atherosclerosis. Therefore, we hypothesized that autophagy-inducing compounds that act on atherosclerosis-relevant cells might have a protective role in the development of atherosclerosis. Here we identified 3,4-dimethoxychalcone (3,4-DC) as an inducer of autophagy in several cell lines from endothelial, myocardial and myeloid/macrophagic origin, as demonstrated by the aggregation of the autophagosome marker GFP-LC3 in the cytoplasm of cells, as well as the downregulation of its nuclear pool indicative of autophagic flux. In this respect, 3,4-DC showed a broader autophagy-inducing activity than another chalcone (4,4- dimethoxychalcone), spermidine and triethylene tetramine. Thus, we characterized the potential antiatherogenic activity of 3,4-DC in two different mouse models, namely, (i) neointima formation with smooth muscle expansion of vein segments grafted to the carotid artery and (ii) genetically predisposed ApoE

Indexed as

AtherosclerosisNeointimaAnimalsAortaAutophagyChalconesDisease Models, AnimalHyperplasiaMiceMice, Inbred C57BL3,4-dimethoxychalconeChalcones

Identifiers

PMID37989732
PMCPMC10663525
OpenAlexW4388910917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.